Genentech secures FDA hearing for Avastin in breast cancer
This article was originally published in Scrip
Executive Summary
Roche's US company Genentech successfully convinced the US FDA to allow the firm to plead its case at a public hearing about why Avastin (bevacizumab) should continue to be marketed as a therapy for patients with HER2-negative metastatic breast cancer.